Competitive Technologies (CTTC), a developer of products and technologies to treat pain, has received the Korea Food & Drug Administration (KFDA) approval for its Calmare device featuring biophysical 'Scrambler Therapy.'
The Calmare device is used to treat chemo-induced peripheral neuropathy (CIPN) and other neuropathic pains.
CTTC’s partner GEOMC, which manufactures the Calmare device, will begin distributing the device in South Korea, as per an agreement.
GEOMC president and CEO Young Lim said the KFDA authorization brings this device to the Asian market by offering a new solution for patients suffering from intractable pain and improving pain treatment.
CTTC CEO Johnnie Johnson said they provide full support to their partners, professional medical trainers, with the guidance of ‘Scrambler Therapy’ technology inventor professor Giuseppe Marineo, have developed standardized procedures for Calmare use, as well as a certification program for medical professionals.